HSBC analyst warns of a downside in Eli Lilly stock to $700. Rajesh Kumar cited 'valuation' as his number 1 concern.

HSBC on Monday double downgraded Eli Lilly and Co. (LLY) stock to ‘Reduce’ from ‘Buy’ and also lowered its price target to ...

The firm said the risk-reward for Eli Lilly (NYSE:LLY) is "not attractive," especially given uncertainties surrounding the future growth of its obesity drug franchise. HSBC noted, "We are not ...

Fintel reports that on April 28, 2025, HSBC downgraded their outlook for Eli Lilly and (NYSE:LLY) from Buy to Reduce. Analyst ...

Eli Lilly And Co (NYSE:LLY) stock is 1.6% lower to trade at $870.31 at last check, after a rare double downgrade from HSBC to ...

Chief executive officers from Nvidia Corp., Johnson & Johnson, Eli Lilly & Co., General Electric Co. and SoftBank Group Corp.

Eli Lilly’s legal actions against Empower Pharmacy and other compounding pharmacies come several months after the FDA ...

Zeit Aktuelle Nachrichten 10:30 HSBC cuts Eli Lilly stock rating to Reduce, target to $700 09:43 UNGLAUBLICHE Sondermeldung bei Eli Lilly Aktie: DAS erwischt Anleger heute eiskalt. Dringend lesen ...

HSBC downgraded several major biotech names this week, citing macroeconomic sensitivities, tariff risks, and growing pressure from regulatory changes. Most notably, the bank downgraded Lilly to Reduce ...